,

Share the Science with the Cerebral Palsy Alliance Research Institute

15 years of research and the incredible advances of umbilical cord blood therapy for cerebral palsy.
,

New Horizons for Cord Blood

Explore the ways cord blood will evolve to meet new needs in the biotherapy industry.
,

Establish product traceability and drive patient safety through automated labeling

To help minimize errors and streamline labeling processes, WellSky and Digi-Trax provide integrated labeling capabilities that promote safe and efficient research and production of cell and gene therapies.
,

Patient engagement strategies to enhance post-transplant outcomes

Communication between patient and provider is essential after a hematopoietic cell transplant. See how you can transform the patient-provider relationship through real-time communication, enhanced information sharing, and improved post-transplant follow-up.
,

Reducing risks of COVID-19 with mesenchymal stem cells

Umbilical cord-derived mesenchymal stem cell infusions may reduce the risk of death and quicken recovery time for COVID-19 patients suffering the most severe conditions. Join Dr. Camillo Ricordi as he examines the potential for stem cells to treat COVID-19 and similar respiratory infections.
,

Combatting GVHD with UCB-derived regulatory T cells

Infection and relapse are the principal obstacles to successful use of allogeneic hematopoietic stem cell transplantation. pioneering researcher John Wagner, MD shares how thymic progenitor cells (Pro-Ts) can repair damaged immune systems, and how UCB can reliably provide large numbers of Pro-Ts suitable for clinical use.
,

Reducing risk of infection in cord blood transplantation

Join Dr. Amanda Olson from the University of Texas MD Anderson Cancer Center, as she shares evidence-based recommendations for the prevention and treatment of opportunistic infections in adult patients undergoing CBT.
,

Implementing and validating a cellular therapy software solution

Download this 5-step process to complete a proper computer system validation that ensures compliance, reliability, and usability.
,

Reducing the cost of post-transplant care with cord blood

Examine the details of a study at the University of Minnesota Medical School that found HCTs involving umbilical cord blood had a lower overall health care burden in the five years after transplant, compared to HCTs with peripheral blood stem cells and bone marrow.
,

The renaissance of public cord blood banks

Cord blood remains an important source for haematopoietic stem cell transplants. Yet HSTCs may be just the tip of the iceberg of the role cord blood will play in future cell therapies. Join Dr. Ngaire Elwood as she shares her research and examines exciting new developments in cord blood banking.
, ,

The renaissance of public cord blood banks

Cord blood remains an important source for haematopoietic stem cell transplants (HSCT), especially as we continue to navigate the worldwide COVID-19 pandemic. Yet HSTCs may be just the tip of the iceberg of the role cord blood will play in future cell therapies. Join Dr. Ngaire Elwood as she shares her research and examines exciting new developments in cord blood banking.
,

Meeting the demand for stem cell donors during a pandemic

COVID-19 created many challenges for cell therapy patients, collection sites, transplant centers, couriers, and donor registries. Discover the supply chain methods NMDP employs to ensure the safe delivery of unrelated donor (URD) products to patients around the world.
,

Targeting neuroinflammation with umbilical cord-derived cell therapies

Examine two investigational cell therapies for inflammatory disease. First, potential use of cord blood monocytes to treat diseases such as leukodystrophies, cerebral palsy, and multiple sclerosis. Then use of cord-tissue-derived mesenchymal stromal cells to reprogram the immune system.
,

Reconstructive Transplantation: New Paradigms, New Technologies

Transplants of the face, hand, and other extremities offer great hope . One obstacle to these procedures is the rejection of multiple tissue types from unrelated doors. Learn how stem cells play a vital role to combat immunosuppression.
, ,

The impact of COVID-19 on the stem cell community

COVID-19 has had a significant global impact on the stem cell supply chain, registries, and recruitment. This webinar looks at the advantages of cord blood-derived stem cells, and why demand has increased during the pandemic.
,

Immune reconstitution after cord blood transplantation

Many factors influence HCT outcomes. This webinar looks at pharmacokinetic studies that show compounds used in the conditioning regimen should follow patient-specific dosing to achieve optimal results.
,

CAR-T cell therapy for lymphoma

CAR-T cell therapy is a promising treatment for certain lymphomas that have not responded to other therapies. This webinar differentiates among the multiple constructs of CAR-T therapy, and when they are effective for the treatment of certain types of lymphoma.
,

Stem Cell Therapies for the Wounded Warrior

Harnessing stem cell therapies to regenerate lost or damaged tissue holds out hope for restoring our Wounded Warriors to full functionality and improving their quality of life. Discover some of the extraordinary work the DoD is doing in cell therapy and regenerative medicine.
,

BMT buyer's guide: Effective strategies for implementing a data management system

Download this checklist of implementation tips to consider before you choose a DMS. A successful implementation will quickly generate new insights that will uncover new operational efficiencies and enhance your compliance with regulatory standards and accrediting bodies.
,

5 Steps to raise the productivity of your apheresis or cell processing program

Your apheresis or cell processing program must excel in many different areas in order to succeed. From donor recruitment and intake, to assessment and collection, these functions are often managed with old-fashioned spreadsheets and paper. This webcast examines WellSky’s approach to resource management, and how we have applied these principles to our cellular therapy solutions.
,

Immune reconstitution after cord blood transplantation

Many factors influence HCT outcomes, such as the selected graft source, type of infused cell subsets, cell doses, and the protocols used for conditioning, immune suppression, and treatment of adverse events. Dr. Boelens shares his investigations to improve immune recovery after HCT to limit both relapse and non-relapse mortality (death due to viral reactivations and graft-versus-host disease).
, ,

Streamlining instrument management

If your lab finds it difficult to test and maintain equipment on a reliable schedule, see how WellSky’s intuitive new Equipment Management solution can improve your regulatory compliance and reduce paperwork overload. Schedule and document all the tasks associated with equipment in one place.
,

Managing hematopoietic diseases through HSC self-renewal

Discover new strategies to manage hematopoietic diseases by targeting the M6A RNA modification pathway. These insights may lead to breakthroughs in the treatment of certain leukemias, lymphomas, and myelomas.
,

Restoring lung growth with intranasal delivery of stem cells

Bronchopulmonary dysplasia (BPD) is a devastating lung condition that develops in premature newborns. Dr. Alvaro Moreira presents on advances in regenerative medicine that may provide a novel approach to BPD.
,

Simplifying data management for BMT programs and cell therapy labs

Good data management is required to maintain quality and process control, evaluate therapies, and to meet regulatory requirements for BMT programs. Learn how a single platform can help.
,

Transitioning to the Seventh Edition NetCord-FACT International Cord Blood Standards

Paul Eldridge, PhD, describes significant changes to the NetCord-FACT international cord blood standards and provides implementation examples.
,

Share the Science: HLA matching for cord blood units

Discover what information is needed to select the most optimal cord blood unit based on HLA profiles.
,

Alternative donor stem cell transplantation

In this presentation, Dr. Karen Ballen discusses the opportunities and challenges presented by allogenic stem cell transplantation and reviews recent data on umbilical cord blood transplant and minimal residual disease.
,

CAR-T data management simplified

The growing use of CAR-T therapy presents new data management challenges for both clinics and labs. WellSky Biotherapies can help solve them.
,

Clinical outcomes after cord blood transplantation

Join us as Dr. Filippo Milano shares how cord blood can be associated with a lower risk of relapse in patients with high risk hematological malignancies, as well as exciting data regarding lower risk of Graft Versus Host Disease (GVHD) in patients receiving cord blood.
,

Share the Science presents: How to ensure proper lab sanitization for cord blood processing labs

Learn best practices for keeping cord blood processing laboratory clean, sanitized, and disinfected - crucial for product quality and safety.
,

Share the Science presents: stem cell therapies for autism

Michael G. Chez, M.D. presents a broad overview of past and current trials applying stem cell therapy to autism spectrum disorders, as well as future therapeutic opportunities. Co-sponsored by Save the Cord Foundation.